Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

Phase 2

Completed

• Conditions: Diphtheria; Haemophilus Influenzae Type b; Tetanus; Poliomyelitis; Acellular Pertussis; Hepatitis B

• Registration Number: NCT00376779
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to show that the immunogenicity of newly formulated DTPa-HBV-IPV/Hib vaccine is as good as the immunogenicity of the currently licensed formulation of the vaccine. The vaccine will be administered as a primary vaccination course to healthy infants at 2, 3 and 4 months of age and its safety and reactogenicity will also be assessed.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-09-14
• Study First Submitted QC: 2006-09-14
• Study First Posted: 2006-09-15
• Study Start: 2006-10
• Primary Completion: 2007-05
• Study Completion: 2007-05
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-02
• Last Update Posted: 2016-11-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• A healthy male or female between, and including, 8 and 12 weeks of age at the time of the first vaccination.
• Written informed consent obtained from the parents/guardians of the subject.
• Born after a normal gestation period of 36 to 42 weeks.

Read More

Exclusion Criteria

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose.
• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
• Administration/planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose, with the exception of the human rotavirus (HRV) vaccine.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B and/or Haemophilus influenza type b (Hib) vaccination or disease.
• Hepatitis B virus (HBV) vaccination at birth.
• History of seizures or progressive neurological disease.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Antibody concentration/response to all vaccine antigens after vaccination

Secondary Outcome Measures

Name	Time	Method
Solicited (D0-3); unsolicited events (D0-30); serious adverse events (SAEs) (full study)

Trial Locations

Locations (1)

GSK Investigational Site; 🇫🇮 Vantaa, Finland